Tanaka 2017.

Methods	Multicenter, placebo‐controlled RCT, 52 weeks
Participants	Age 18 or over with qualifying SELENA‐SLEDAI score
Interventions	IV belimumab 10 mg/kg or placebo every 28 days, plus standard SLE therapy
Outcomes	Reduction in steroid dose, adverse events
Notes	N = 677; belimumab effective in steroid reduction

IV: intravenous
RCT: randomized controlled trial
SELENA‐SLEDAI: Safety of Estrogen in Lupus National Assessment (SELENA) ‐ Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
SLE: systemic lupus erythematosus
SLEDAI‐2K: Safety of Estrogen in Lupus National Assessment (SELENA) ‐ Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2000